French biotech company TxCell (Euronext Paris: TXCL) announced yesterday that it has entered into an exclusive option agreement with Yeda Research and Development Co, the technology transfer arm of the Weizmann Institute of Science in Rehovot, Israel.
Financial terms of the option and of the license were not disclosed.
Resulting from the exclusive option agreement, TxCell will gain exclusive access to a CAR-Treg patent for suppression of autoimmune and inflammatory diseases originated in the Weizmann Institute of Science laboratory of Zelig Eshhar.
Professor Eshhar pioneered the CAR (Chimeric Antigen Receptor) approach. His achievements were recognized by several international awards, including the CAR Pioneering award by the ATTACK European Consortium, the Teva and Massry prizes and, most recently, the Israel Prize in life sciences.
The patent application under the option that TxCell has obtained covers redirected, genetically engineered T regulatory cells (CAR-Treg) and their use in suppression of autoimmune and inflammatory diseases.
“Entering into this exclusive option agreement with the Weizmann Institute of Science, one of the world’s leading academic research centers, is a very important milestone for TxCell,” said Arnaud Foussat, chief scientific officer of TxCell, adding: “In view of extending our existing Treg-cell platform, TxCell has committed to evaluate and establish the significance of CAR-Treg cell products in inflammation and auto-immunity.”
“TxCell, through its unique expertise and management of the research and clinical development of Treg based cellular immunotherapy products, is ideally positioned to develop CAR-Treg product for chronic inflammation and autoimmune diseases,” said Amir Naiberg, chief executive of Yeda.
The option agreement grants TxCell until June 30, 2016 to opt-in at predefined terms.Tags: Biotechnology IP, Europe IP, France IP, Immunologicals IP, Inflammatory diseases, Israel IP, Licensing, Patents, TxCell, Weizmann Institute of Science Israel, Yeda Research and Development, Zelig Eshhar